Human protease inhibitor and polynucleotides encoding the same

Details Human protease inhibitor and polynucleotides encoding the same Human protease inhibitor and polynucleotides encoding the same

2001-12-18

2003-06-24

Prouty, Rebecca E. (Department: 1652)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C536S023500, C435S320100, C435S325000, C435S252300

Reexamination Certificate

active

06583269

ABSTRACT:

1. INTRODUCTION
The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins sharing sequence similarity with animal protease inhibitor proteins. The invention encompasses the described polynucleotides, host cell expression systems, the encoded protein, fusion proteins thereof, polypeptides and peptides, antibodies to the encoded protein and corresponding peptides, and genetically engineered animals that either lack or overexpress the disclosed genes, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed genes, which can be used for diagnosis, drug screening, clinical trial monitoring, the treatment of diseases and disorders, and cosmetic or nutriceutical applications.
2. BACKGROUND OF THE INVENTION
Protease inhibitors have been implicated in a variety of biological processes and anomalies such as development and infectious diseases.
3. SUMMARY OF THE INVENTION
The present invention relates to the discovery, identification, and characterization of nucleotides that encode a novel human protein, and the corresponding amino acid sequence of this protein. The novel human protein (NHP) described for the first time herein shares structural similarity with animal protease inhibitors and other animal proteins including, but not limited to, antithrombin, plasminogen activator inhibitors as well as neurite promoting-factor. The novel human nucleic acid sequences described herein encode a protein/open reading frame (ORFs) of 425 amino acids in length (see SEQ ID NO:2).
The invention also encompasses agonists and antagonists of the described NHPs, including small molecules, large molecules, mutant NHPS, or portions thereof, that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and open reading frame or regulatory sequence replacement constructs) or to enhance the expression of the described NHPs (e.g., expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP sequence, or “knock-outs” (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cells (“ES cells”) lines that contain gene trap mutations in a murine homolog of at least one of the described NHPs. When the unique NHP sequences described in SEQ ID NOS:1-3 are “knocked-out” they provide a method of identifying phenotypic expression of the particular gene as well as a method of assigning function to previously unknown genes. In addition, animals in which the unique NHP sequences described in SEQ ID NOS:1-3 are “knocked-out” provide a unique source in which to elicit antibodies to homologous and orthologous proteins which would have been previously viewed by the immune system as “self” and therefore would have failed to elicit significant antibody responses. To these ends, gene trapped knockout ES cells have been generated in murine homologs of the described NHP.
Additionally, the unique NHP sequences described in SEQ ID NOS:1-11 are useful for the identification of protein coding sequence and mapping a unique gene to a particular chromosome (the gene encoding the described NHP is apparently encoded on human chromosome 18, see GENBANK accession number XM
—
055022). These sequences identify actual, biologically verified, and therefore relevant, exon splice junctions as opposed to those that may have been bioinformatically predicted from genomic sequence alone. The sequences of the present invention are also useful as additional DNA markers for restriction fragment length polymorphism (RFLP) analysis, and in forensic biology.
Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.
4. DESCRIPTION OF THE SEQUENCE LISTINGS
The Sequence Listing provides sequences encoding the described NHP amino acid sequence. SEQ ID NO: 3 describes a NHP ORF and flanking regions.


REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4594595 (1986-06-01), Struckman
patent: 4631211 (1986-12-01), Houghten
patent: 4689405 (1987-08-01), Frank et al.
patent: 4713326 (1987-12-01), Dattagupta et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5700637 (1997-12-01), Southern
patent: 5744305 (1998-04-01), Fodor et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5869336 (1999-02-01), Meyer et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5948767 (1999-09-01), Scheule et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6150584 (2000-11-01), Kucherlapati et al.
Askew Y. A. et al. SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine protease, J. Biol. Chem. 2001, 276/52, 49320-49330.*
Seffernick J. L. et al. Melanine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different, J. Bact. (2001, 183/8, 2405-2410).*
Bird et al, 1988, “Single-Chain Antigen-Binding Proteins”, Science 242:423-426.
Bitter et al, 1987, “Expression and Secretion Vectors for Yeast”, Methods in Enzymology 153:516-544.
Colbere-Garapin et al, 1981, “A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells”, J. Mol. Biol. 150:1-14.
Gautier et al, 1987, “&agr;-DNA IV:&agr;-anomeric and &bgr;-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding”, Nucleic Acids Research 15(16):6625-6641.
Gordon, 1989, “Transgenic Animals”, International Review of Cytology, 115:171-229.
Greenspan et al, 1993, “Idiotypes: structure and immunogenicity”, FASEB Journal 7:437-444.
Gu et al, 1994, “Deletion of a DNA Polymerase &bgr; Gene Segment in T Cells Using Cell Type-Specific Gene Targeting”, Science 265:103-106.
Huse et al, 1989, “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science 246:1275-1281.
Huston et al, 1988, “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, Proc. Natl. Acad. Sci. USA 85:5879-5883.
Inoue et al, 1987, “Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H”, FEBS Letters 215(2):327-330.
Inoue et al, 1987, “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides”, Nucleic Acids Research 15(15):6131-6149.
Inouye & Inouye, 1985, “Up-promoter mutations in the lpp gene ofEscherichia coli”, Nucleic Acids Research 13(9):3101-3110.
Janknecht et al, 1991, “Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus”, PNAS 88:8972-8976.
Kohler & Milstein, 1975, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature 256:495-497.
Lakso et al, 1992, “Targeted oncogene activation by site-specific recombinant in transgenic mice”, Proc. Natl. Acad. Sci. USA 89:6232-6236.
Lavitrano et al, 1989, “Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Tra

Affiliated with

Also associated with

Rating

Human protease inhibitor and polynucleotides encoding the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human protease inhibitor and polynucleotides encoding the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human protease inhibitor and polynucleotides encoding the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3094118